Product image of Icatibant Accord (Icatibant) supplied by GNH India

Icatibant Accord

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Accord (Icatibant)

Icatibant, the active ingredient in Icatibant Accord, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema attacks in patients with confirmed HAE.

GNH India supplies Icatibant Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards, is manufactured under GMP conditions, and our distribution network ensures timely delivery with appropriate cold‑chain handling where required.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to manage hereditary angioedema, a bradykinin‑mediated disorder that causes sudden swelling.

  • Hereditary angioedema type I attacks: provides rapid reduction of swelling and associated pain, improving airway safety.
  • Hereditary angioedema type II attacks: accelerates resolution of edema episodes, decreasing duration of symptoms.
  • Bradykinin‑mediated angioedema attacks: alleviates swelling when caused by excess bradykinin, offering prompt symptom control.
  • Acute HAE episodes in adults: enables self‑administration for timely treatment of attacks.

How It Works

  • Icatibant selectively binds to the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin from activating the receptor. By blocking this pathway, it inhibits bradykinin‑induced vasodilation and increased vascular permeability, thereby reducing the fluid extravasation that leads to angioedema. The antagonism is competitive and reversible, allowing normal receptor function to resume after the drug is cleared.

Side Effects

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects

  • Injection site pain: mild to moderate discomfort.
  • Redness or erythema: localized skin reddening.
  • Headache: transient headache after dosing.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response.
  • Airway angioedema: swelling that may compromise breathing.
  • Severe hypotension: sudden drop in blood pressure.

Precautions & Warnings

Before using Icatibant Accord, several safety considerations should be observed.

  • Confirm diagnosis: ensure patient has hereditary angioedema before administration.
  • Monitor for hypersensitivity: observe for signs of allergic reaction after injection.
  • Avoid in known hypersensitivity: do not use in patients with previous icatibant allergy.
  • Use with caution in pregnancy or lactation: limited safety data, weigh benefits and risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid)

  • ACE inhibitors: increase bradykinin levels, raising risk of angioedema.
  • Angiotensin receptor blockers: may potentiate bradykinin‑mediated effects.
  • C1‑esterase inhibitor concentrates: concurrent use may be unnecessary and increase adverse event risk.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing contraceptives: can affect frequency of HAE attacks.
  • Other bradykinin B2 antagonists: combined effect may enhance pharmacologic activity.

Frequently Asked Questions

Icatibant Accord is prescribed for the acute treatment of hereditary angioedema (HAE) attacks in patients with a confirmed diagnosis. By targeting the underlying bradykinin pathway, it helps to quickly reduce swelling, pain, and potential airway obstruction associated with HAE episodes.

Icatibant works by selectively blocking the bradykinin B2 receptor on vascular endothelial cells. This inhibition prevents bradykinin from causing vasodilation and increased vascular permeability, which are the primary mechanisms that lead to the rapid swelling seen in hereditary angioedema.

The dosage of Icatibant Accord is determined by the prescribing healthcare professional based on the patient’s condition, weight, and clinical response. The prescriber will specify the exact amount and frequency required for each individual treatment episode.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful consideration.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑esterase inhibitor concentrates replace a deficient protein. Icatibant offers the advantage of subcutaneous self‑administration and rapid onset, but the choice of therapy depends on individual patient factors and physician judgment.

Icatibant Accord should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and potency.

Icatibant Accord is administered as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after appropriate instruction, using the supplied pre‑filled syringe.

The most serious risks include severe allergic reactions such as anaphylaxis, airway angioedema that can compromise breathing, and sudden hypotension. Patients should be monitored after injection, and any signs of these reactions require immediate medical attention.

Icatibant should not be used in individuals with a known hypersensitivity to icatibant or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to other bradykinin B2 receptor antagonists.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT